Page 26

20

Hasta que Campuses no la curemos, NO PARAREMOS LINES OF WORK / Our /scientific

also effective against acute myeloid leukaemia in the preclinical trials carried out in the laboratory. Given that these results are very promising, the Josep Carreras Foundation and the Josep Carreras Leukaemia Research Institute agreed to create Leukos Biotech in order to develop the project further and take all the steps necessary to lead to clinical trials in order to test the efficacy of this new treatment in patients with acute myeloid leukaemia.

Dr Enric Carreras (7) leads the research group studying the role played by endothelial cells (the cells which coat the inner lining of blood vessels) in the various complications observed during haemapoeitic progenitor transplants.

In 2015 Dr Enric Carreras also published an important work in the British Journal of Haematology (BJH) entitled “How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.” The work is an update on all the existing knowledge about one of the most widely feared complications after HCT: veno-occlusive disease.

In 2015 BET published an article with the stimulating title: “What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance.”

In this publication, Dr Enric Carreras—recognised as one of the world’s leading experts on the subject—articulated his personal recommendations on how to treat these patients.

New work by the BET. (6)(Barcelona Endothelium Team)

SCIENTIFIC ADVANCES & COLLABORATIONS ON THE CLINIC-UB CAMPUS

haemapoietic transplants. It is known that DF acts as a protective endothelial agent, although its precise action mechanism has yet to be elucidated. The aim of this study was to investigate the interaction between DF and endothelial cells. The results contribute to a better understanding of the precise action mechanisms of DF as a potential preventive and therapeutic agent in the different underlying pathological situations of endothelial damage.

The European Medicines Agency has authorised the use of defibrotide (DF) to treat sinusoidal obstruction syndrome, a frequent complication after

6

7

Annual Activity Report 2015  
Annual Activity Report 2015  
Advertisement